Difference between revisions of "DZI19-121-Case-10"

From MGH Learn Pathology
(Automatic edit to upgrade to new templates)
(Updating subject, access, and performer)
Line 21: Line 21:
 
ATRX: nuclear expression retained (immunohistochemistry, consistent with wildtype)
 
ATRX: nuclear expression retained (immunohistochemistry, consistent with wildtype)
 
|reasonCode=(ASCP CASE 9) 35 year old woman presents with new onset of tonic-clonic seizures
 
|reasonCode=(ASCP CASE 9) 35 year old woman presents with new onset of tonic-clonic seizures
|subject=public
+
|subject=MGH
|performer=Mml55
+
|performer=MML55
 
|authoredOn=September 11, 2019 01:58:41 PM
 
|authoredOn=September 11, 2019 01:58:41 PM
 
|requester=Em99
 
|requester=Em99
 
|sequence=10
 
|sequence=10
 +
|access=public
 
}}
 
}}
 
{{Media
 
{{Media

Revision as of 15:09, June 21, 2022

DZI19-121-Case-10
(ASCP CASE 9) 35 year old woman presents with new onset of tonic-clonic seizures
Integrated diagnosis:

PLEOMOPHIC XANTHOASTROCYTOMA, BRAF V600E MUTANT

Histological diagnosis: Pleomorphic xanthoastrocytoma

WHO histological grade: II

Molecular information: BRAF V600E: MUTANT (sequencing) IDH: wildtype (IDH1/2 sequencing) P53: weak in rare tumor cells (immunohistochemistry, consistent with wildtype)

ATRX: nuclear expression retained (immunohistochemistry, consistent with wildtype)
December 31, 1969 7:00:00 PM